0.0000
- Close
AMS
data delayed by 15 mins -
Disclaimer
Currency in
| Range | - |
| 52 week | 0.00 - 0.74 |
| Open | - |
| Vol / Avg. | 0.00/181,901.00 |
| Mkt cap | - |
| P/E | - |
| Div/yield | - |
| EPS | 0.00 |
| Shares | 23.71M |
| Beta | - |
| Inst. own | - |
Key stats and ratios
| Q4 (Dec '11) | 2011 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | 171.53% | 0.00% |
| Return on average equity | 1419.04% | 0.00% |
| Employees | 85 | - |
| Carbon Disclosure Rating | - | - |
Address
Meibergdreef 61
AMSTERDAM, 1105 BA
Netherlands
+31-20-5667394 (Phone)
+31-20-5669272 (Fax)
AMSTERDAM, 1105 BA
Netherlands
+31-20-5667394 (Phone)
+31-20-5669272 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Amsterdam Molecular Therapeutics AMT Holding NV is a Netherlands-based company, which was formerly engaged in human gene therapy. The Company developed Glybera, for the treatment of Lipoprotein Lipase Deficiency (LPLD). On April 5, 2012, the Company disposed of its entire business and operations to uniQure B.V., and as of this date, the Company was in liquidation.
Officers and directors
| Jorn Aldag | Joint Liquidator | |
| Piers J. Morgan | Joint Liquidator |